NZ207258A - Substituted imidazoles - Google Patents
Substituted imidazolesInfo
- Publication number
- NZ207258A NZ207258A NZ20725881A NZ20725881A NZ207258A NZ 207258 A NZ207258 A NZ 207258A NZ 20725881 A NZ20725881 A NZ 20725881A NZ 20725881 A NZ20725881 A NZ 20725881A NZ 207258 A NZ207258 A NZ 207258A
- Authority
- NZ
- New Zealand
- Prior art keywords
- guanidino
- mmol
- thiazole
- mixture
- formula
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 86
- 239000002253 acid Substances 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- 239000000203 mixture Substances 0.000 description 67
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 66
- 239000000243 solution Substances 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 238000001914 filtration Methods 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- -1 hydroxymethy1 Chemical group 0.000 description 27
- 238000010992 reflux Methods 0.000 description 27
- 239000002244 precipitate Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 239000012458 free base Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- RGHIROSMHZJRQK-UHFFFAOYSA-N 2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylic acid Chemical compound NC(=N)NC1=NC(C(O)=O)=CS1 RGHIROSMHZJRQK-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000002198 insoluble material Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- UJLNITKVGULKNI-UHFFFAOYSA-N 2-[4-(hydrazinecarbonyl)-1,3-thiazol-2-yl]guanidine Chemical compound NNC(=O)C1=CSC(NC(N)=N)=N1 UJLNITKVGULKNI-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010020601 Hyperchlorhydria Diseases 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 210000004211 gastric acid Anatomy 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- ZYVPOPWDOQZIQC-UHFFFAOYSA-N 1,3-thiazole;dihydrochloride Chemical compound Cl.Cl.C1=CSC=N1 ZYVPOPWDOQZIQC-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 4
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 4
- 108010079943 Pentagastrin Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- VFHWCZMTMRVBAN-UHFFFAOYSA-N acetaldehyde hydrobromide Chemical compound Br.CC=O VFHWCZMTMRVBAN-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001262 anti-secretory effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 229910000039 hydrogen halide Inorganic materials 0.000 description 4
- 239000012433 hydrogen halide Substances 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- KSXJITOVDCAVAY-UHFFFAOYSA-N n,2-bis(diaminomethylideneamino)-1,3-thiazole-4-carboxamide Chemical compound NC(=N)NNC(=O)C1=CSC(NC(N)=N)=N1 KSXJITOVDCAVAY-UHFFFAOYSA-N 0.000 description 4
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 4
- 229960000444 pentagastrin Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000010453 quartz Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002731 stomach secretion inhibitor Substances 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- TUFOJIVMBHBZRQ-UHFFFAOYSA-N 1-(1h-imidazol-5-yl)ethanone Chemical compound CC(=O)C1=CN=CN1 TUFOJIVMBHBZRQ-UHFFFAOYSA-N 0.000 description 3
- VDJFKJZIBGJUEJ-UHFFFAOYSA-N 2-[4-(2-azidoacetyl)-1,3-thiazol-2-yl]guanidine Chemical compound NC(=N)NC1=NC(C(=O)CN=[N+]=[N-])=CS1 VDJFKJZIBGJUEJ-UHFFFAOYSA-N 0.000 description 3
- HNCBHFLGVNAVNT-UHFFFAOYSA-N 2-[4-(2-bromoacetyl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.NC(=N)NC1=NC(C(=O)CBr)=CS1 HNCBHFLGVNAVNT-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 125000005233 alkylalcohol group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- LBSBQVAGEVSBQP-UHFFFAOYSA-N ethyl 2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(N=C(N)N)=N1 LBSBQVAGEVSBQP-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RZMOICJDRADLCT-UHFFFAOYSA-N 1,4-Dibromodiacetyl Chemical compound BrCC(=O)C(=O)CBr RZMOICJDRADLCT-UHFFFAOYSA-N 0.000 description 2
- KMNCWQZBROZORX-UHFFFAOYSA-N 1,4-dibromo-3,3-diethoxybutan-2-one Chemical compound CCOC(CBr)(OCC)C(=O)CBr KMNCWQZBROZORX-UHFFFAOYSA-N 0.000 description 2
- HUKNDBAKSCHISX-UHFFFAOYSA-N 1-(5-methyl-1h-imidazol-4-yl)ethanone Chemical compound CC(=O)C=1N=CNC=1C HUKNDBAKSCHISX-UHFFFAOYSA-N 0.000 description 2
- MGSUZKWFACFSDH-UHFFFAOYSA-N 1-[2-(hydroxymethyl)-1h-imidazol-5-yl]ethanone Chemical compound CC(=O)C1=CNC(CO)=N1 MGSUZKWFACFSDH-UHFFFAOYSA-N 0.000 description 2
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N 2,5-dimethyl-1h-imidazole Chemical compound CC1=CN=C(C)N1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 2
- WVXRGBJXUZSUGQ-UHFFFAOYSA-N 2-[4-(1h-imidazole-5-carbonyl)-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.S1C(NC(=N)N)=NC(C(=O)C=2N=CNC=2)=C1 WVXRGBJXUZSUGQ-UHFFFAOYSA-N 0.000 description 2
- FQOXJJNWHXRGIV-UHFFFAOYSA-N 2-[4-(2-aminoacetyl)-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.NCC(=O)C1=CSC(NC(N)=N)=N1 FQOXJJNWHXRGIV-UHFFFAOYSA-N 0.000 description 2
- MVTGVDHNHMILAT-UHFFFAOYSA-N 2-bromo-1-(2-methyl-1h-imidazol-5-yl)ethanone;hydrobromide Chemical compound Br.CC1=NC(C(=O)CBr)=CN1 MVTGVDHNHMILAT-UHFFFAOYSA-N 0.000 description 2
- NHZTZQDWMOWTJF-UHFFFAOYSA-N 2-bromo-1-(5-methyl-1h-imidazol-4-yl)ethanone Chemical compound CC=1N=CNC=1C(=O)CBr NHZTZQDWMOWTJF-UHFFFAOYSA-N 0.000 description 2
- DMJVNZUWGQHJJB-UHFFFAOYSA-N 3-bromo-1-(1h-imidazol-5-yl)propane-1,2-dione;hydrobromide Chemical compound Br.BrCC(=O)C(=O)C1=CNC=N1 DMJVNZUWGQHJJB-UHFFFAOYSA-N 0.000 description 2
- VSEUYEAKIAUEHZ-UHFFFAOYSA-N 3-bromo-4-ethoxybut-3-en-2-one Chemical compound CCOC=C(Br)C(C)=O VSEUYEAKIAUEHZ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- QIRSDXBXWUTMRE-UHFFFAOYSA-N benzylcyanamide Chemical compound N#CNCC1=CC=CC=C1 QIRSDXBXWUTMRE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- OSMJIXXVEWORDJ-UHFFFAOYSA-N 1-(1h-imidazol-2-yl)ethanone Chemical compound CC(=O)C1=NC=CN1 OSMJIXXVEWORDJ-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HEUBFSYOZRPRTD-UHFFFAOYSA-N 1-(2,5-dimethyl-1h-imidazol-4-yl)ethanone Chemical compound CC(=O)C=1NC(C)=NC=1C HEUBFSYOZRPRTD-UHFFFAOYSA-N 0.000 description 1
- MZJZNADJWQEIIG-UHFFFAOYSA-N 1-(2-methyl-1h-imidazol-5-yl)ethanone Chemical compound CC(=O)C1=CN=C(C)N1 MZJZNADJWQEIIG-UHFFFAOYSA-N 0.000 description 1
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 1
- VZOPVKZLLGMDDG-UHFFFAOYSA-N 1-oxido-4-phenylpyridin-1-ium Chemical compound C1=C[N+]([O-])=CC=C1C1=CC=CC=C1 VZOPVKZLLGMDDG-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WJBYWVCIUVWULC-UHFFFAOYSA-N 2-(4-acetyl-1,3-thiazol-2-yl)guanidine;dihydrochloride Chemical compound Cl.Cl.CC(=O)C1=CSC(N=C(N)N)=N1 WJBYWVCIUVWULC-UHFFFAOYSA-N 0.000 description 1
- MZEWIHBWBREJIS-UHFFFAOYSA-N 2-[4-(1,3-thiazol-2-yl)-1,3-thiazol-2-yl]guanidine Chemical group S1C(NC(=N)N)=NC(C=2SC=CN=2)=C1 MZEWIHBWBREJIS-UHFFFAOYSA-N 0.000 description 1
- AXCNMJYJGZCULB-UHFFFAOYSA-N 2-[4-(1,3-thiazol-4-yl)-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(C=2N=CSC=2)=C1 AXCNMJYJGZCULB-UHFFFAOYSA-N 0.000 description 1
- LOLURPLOTOYRRI-UHFFFAOYSA-N 2-[4-(1h-imidazol-2-yl)-1,3-thiazol-2-yl]guanidine Chemical group S1C(N=C(N)N)=NC(C=2NC=CN=2)=C1 LOLURPLOTOYRRI-UHFFFAOYSA-N 0.000 description 1
- GQOVTZHEZPKTGS-UHFFFAOYSA-N 2-[4-(2-amino-1,3-thiazol-4-yl)-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(C=2N=C(N)SC=2)=C1 GQOVTZHEZPKTGS-UHFFFAOYSA-N 0.000 description 1
- KVKPPTWDKZOEQA-UHFFFAOYSA-N 2-[4-(2-amino-1,3-thiazol-4-yl)-1,3-thiazol-2-yl]guanidine;dihydrobromide Chemical compound Br.Br.S1C(NC(=N)N)=NC(C=2N=C(N)SC=2)=C1 KVKPPTWDKZOEQA-UHFFFAOYSA-N 0.000 description 1
- OKRAYSIXRKJKBM-UHFFFAOYSA-N 2-[4-(2-amino-1h-imidazole-5-carbonyl)-1,3-thiazol-2-yl]guanidine Chemical compound S1C(NC(=N)N)=NC(C(=O)C=2N=C(N)NC=2)=C1 OKRAYSIXRKJKBM-UHFFFAOYSA-N 0.000 description 1
- VDMGUZLKLQMVJV-UHFFFAOYSA-N 2-[4-(5-methyl-1h-1,2,4-triazol-3-yl)-1,3-thiazol-2-yl]guanidine Chemical compound CC1=NNC(C=2N=C(NC(N)=N)SC=2)=N1 VDMGUZLKLQMVJV-UHFFFAOYSA-N 0.000 description 1
- NPAHPKSIQYJDLO-UHFFFAOYSA-N 2-[4-(5-methyl-1h-imidazol-4-yl)-1,3-thiazol-2-yl]guanidine Chemical compound N1=CNC(C=2N=C(NC(N)=N)SC=2)=C1C NPAHPKSIQYJDLO-UHFFFAOYSA-N 0.000 description 1
- YIUSMHXFPSORGW-UHFFFAOYSA-N 2-[4-(5-propyl-1h-1,2,4-triazol-3-yl)-1,3-thiazol-2-yl]guanidine Chemical compound CCCC1=NNC(C=2N=C(NC(N)=N)SC=2)=N1 YIUSMHXFPSORGW-UHFFFAOYSA-N 0.000 description 1
- UDFQWTOIRFJRHP-UHFFFAOYSA-N 2-[4-[2-(hydroxymethyl)-1h-imidazol-5-yl]-1,3-thiazol-2-yl]guanidine;hydrobromide Chemical compound Br.S1C(NC(=N)N)=NC(C=2N=C(CO)NC=2)=C1 UDFQWTOIRFJRHP-UHFFFAOYSA-N 0.000 description 1
- QJWIMGXDWBBGAN-UHFFFAOYSA-N 2-bromo-1-(2,5-dimethyl-1h-imidazol-4-yl)ethanone Chemical compound CC1=NC(C)=C(C(=O)CBr)N1 QJWIMGXDWBBGAN-UHFFFAOYSA-N 0.000 description 1
- QTVGLOOZIYZYRQ-UHFFFAOYSA-N 2-bromo-1-[2-(hydroxymethyl)-1h-imidazol-5-yl]ethanone;hydrobromide Chemical compound Br.OCC1=NC(C(=O)CBr)=CN1 QTVGLOOZIYZYRQ-UHFFFAOYSA-N 0.000 description 1
- ZWHNENLFDCPADO-UHFFFAOYSA-N 2-bromo-1-ethoxybut-1-ene Chemical compound CCOC=C(Br)CC ZWHNENLFDCPADO-UHFFFAOYSA-N 0.000 description 1
- DRWDZFNIPARKSG-UHFFFAOYSA-N 2-hydroxyethanimidamide;hydrochloride Chemical compound Cl.NC(=N)CO DRWDZFNIPARKSG-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- RXXQKTSOBMGARS-UHFFFAOYSA-N 3-bromo-4-hydroxybut-3-en-2-one Chemical compound CC(=O)C(Br)=CO RXXQKTSOBMGARS-UHFFFAOYSA-N 0.000 description 1
- XLKLSWJVKFKHAE-UHFFFAOYSA-N 3-bromo-4-methoxybut-3-en-2-one Chemical compound COC=C(Br)C(C)=O XLKLSWJVKFKHAE-UHFFFAOYSA-N 0.000 description 1
- HSWYXPGZYQGDRJ-UHFFFAOYSA-N 4-(2H-triazol-4-yl)-1,3-thiazole Chemical compound S1C=NC(C=2N=NNC=2)=C1 HSWYXPGZYQGDRJ-UHFFFAOYSA-N 0.000 description 1
- VHBQPPMMBOGTCI-UHFFFAOYSA-N 4-bromopentane-2,3-dione Chemical compound CC(Br)C(=O)C(C)=O VHBQPPMMBOGTCI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- BXOBQDOEBJELFC-UHFFFAOYSA-N acetaldehyde;dihydrochloride Chemical compound Cl.Cl.CC=O BXOBQDOEBJELFC-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 1
- PQZVCRPSQXDXJL-UHFFFAOYSA-N butylcyanamide Chemical compound CCCCNC#N PQZVCRPSQXDXJL-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N dimethylglyoxal Natural products CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- JEZVIUQRUWOXRY-UHFFFAOYSA-N ethyl butanimidate Chemical compound CCCC(=N)OCC JEZVIUQRUWOXRY-UHFFFAOYSA-N 0.000 description 1
- YGBFFMMKLWVKGU-UHFFFAOYSA-N ethyl butanimidate;hydrochloride Chemical compound [Cl-].CCCC(=[NH2+])OCC YGBFFMMKLWVKGU-UHFFFAOYSA-N 0.000 description 1
- JOGZZTFIGKYTSV-UHFFFAOYSA-N ethylcyanamide Chemical compound CCNC#N JOGZZTFIGKYTSV-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
- MCLITRXWHZUNCQ-UHFFFAOYSA-N methylcyanamide Chemical compound CNC#N MCLITRXWHZUNCQ-UHFFFAOYSA-N 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XGZVNVFLUGNOJQ-UHFFFAOYSA-N n,n-dimethylformamide;ethyl acetate Chemical compound CN(C)C=O.CCOC(C)=O XGZVNVFLUGNOJQ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- RYYCFQTWLMFJIG-UHFFFAOYSA-N propylcyanamide Chemical compound CCCNC#N RYYCFQTWLMFJIG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £07258
8
t
Priority Dats^s): (f"(*?
Coirifiicta Specification Filed: fi.'JP.'fiJ
CIB»S: ^9lA&x&f.kt*.. .©.
Potion D«te:..J.?.®f.EBJ??a.
P.O. JourrjE!, He: '.^,7
PT/9 cr j w.
'34
19
s
$ III S3
Under the provisions of Regtf^
lation 23 (!) the
Spcc-Kk* Is: boc. ar.tc-daied to J3 Oe/s/k^.... \<#l
Divided out o£ No.: 198629
Date: 13 October 1981
NEW ZEALAND PATENTS ACT, 1953
Ontffe
(fzcuxSors to* 2-
COMPLETE SPECIFICATION GUANIDINO-4-HETEROARYLTHIAZOLES"
3SX/ We, PFIZER INC. , a corporation organized under the laws of the State of Delaware, United States of America, of 235 East 42nd Street, New York, State, of New York, United States of America,
hereby declare the invention for which 31C/ we pray that a patent may be granted to xecec/us, and the method by which it is to be performed, to be particularly described in and by the following statement:-
1 -
(followed by page la)
New Zealand Patent Specification No. 198,629 relates to novel 2-guanidino-4-heteroarylthiazoles having activity as antisecretory agents and histamine antagonists and which are accordingly useful in the prevention and treatment of gastric hyperacidity and peptic ulcers.
Chronic gastric and duodenal ulcers, together known as peptic ulcers, are a common ailment for which a variety of treatments, including dietary measures, drug therapy and surgery, may be employed, depending on the severity of the condition. Particularly valuable therapeutic agents useful for the treatment of gastric hyperacidity and peptic ulcers are the histamine J^-receptor antagonists, which act to block the action of the physiologically active compound histamine at the I^-receptor sites in the animal body and to thereby inhibit the secretion of gastric acid.
The invention of New Zealand Patent
Specification No. 198629 relates to novel 2-guanidino-4-heteroary1thiazoles useful as histamine-H2 antagonists and as antisecretory agents and which are therefore useful in the treatment of peptic ulcers and other conditions caused or aggravated by gastric hyperacidity. More specifically, the novel compounds of the invention are those of the formula wherein X is S or NH; Y is CH, C.CH^ or N; R is hydrog hydroxymethy1, alkyl of 1 to 6 carbon atoms, -(Oi^) Ar -NH^, -NHR^ or -NRCOR^, wherein R^ is alkyl of 1 to 6 carbon atoms or ~(CH2)mAr; wherein n is an integer from 2 to 4; m is zero or an integer from 1 to 4; and Ar is phenyl or phenyl monosubstituted with chloro, bromo, fluoro, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms; provided that when Y is N, X is NH and m is other than zero; and when X is S, R is other than hydroxymethy 1, alkyl or -{CH2)nAr.
One group of compounds of interest are those wherein Y is CH and X is S, that is 2-guanidino-4-thiazolyl-thiazole and derivatives thereof. Preferred compounds include those where R is hydrogen, -NH2, -NHCH3 and NHCOCH3.
R
H2NdNH
I
A further group of compounds of particular interest embraced by the invention are those wherein Y
is CH and X is NH, that is 2-guanidino-4-imidazolyl-thiazole and derivatives thereof. Preferred compounds 5 include those wherein R is'hydrogen, hydroxymethyl,
methyl, -NH^; -NHCH^ or -NHCOCH^, especially hydrogen, hydroxymethyl, methyl or -N^.
Another group of compounds of the invention are those wherein Y is C.CH^ and X is NH, that is 2-10 g-aanidino-4-(4-methyl-5-imidazolyl)-thiazole and derivatives thereof. Preferred compounds include those wherein R is hydrogen or methyl.
Another group of compounds of the invention are those wherein Y is N and X is NH, that is 2-guanidino-15 4-triazolyl-thiazole and derivatives thereof. Preferred compounds include those wherein R is -11or methyl.
Also embraced by the invention are pharma ceutical compositions comprising a gastric antisecretory effective amount of a compound of formula I, or a pharma-20 ceutically acceptable acid addition salt thereof,
together with a pharmaceutically acceptable carrier or diluent. Preferred pharmaceutical compositions are those containing the preferred compounds of formula I as described hereinabove, including those 25 wherein Y.is CH, X is S and R is -N^; Y is CH, X is NH and R is hydrogen, hydroxymethyl, methyl or —NH2; and where Y is N, X is NH and R is -NH2 or methyl.
The invention also comprises the method of treating gastric hyperacidity in a nonhuman animal in need 30 of treatment comprising administering to the animal a gastric antisecretory effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. Preferred compounds for use in this method of treatment are the preferred compounds of formula I 35 as described herein above.
207258
New Zealand Patent Specification No. 207257 relates to novel intermediates useful in the preparation of the compounds of formula I. More particularly, such compounds are those of the formula
NH
l2L
H,NCNH V \\ II
and the acid addition salts thereof, wherein R2 is —COCH(Rn)R^ or -CONHR^, wherein R" is hydrogen or methyl, R3 is halo, N3 or -NH2 and R4 is -NH2 or -MBC(NH)NH2.
The present invention relates to further intermediates useful for the preparation of compounds of the formula I. The compounds of the invention are those of the formula
CH2R5
III
I
and the acid addition salts thereof, wherein R is hydrogen, hydroxymethy1, alkyl of 1 to 6 carbon atoms or -(CH_) Ar, wherein n and Ar are as previously
JHl defined; R" is hydrogen or methyl; and Rg is halo, preferably chloro or bromo. Preferred intermediates of formula III are those wherein R is hydrogen or methyl and R5 is chloro or bromo.
Novel 3-halo-4-n-alkoxy-3-buten-2-ones, wherein the n-alkoxy group has from 1 to 4 carbon atoms, preferably methoxy or ethoxy, especially the compounds where the halo group is chloro or bromo are useful in the preparation of
Kf? ' ;1'-C'V\\
the intermediates of formula III. , V'
-v -77 ** ^
1 ■ ~v /Lo\
Detailed Description of the Invention The novel compounds of formula I wherein Y is CH or C.CH^ and x is NH or S are prepared from the corresponding novel intermediates of formula II wherein 1*2 is —COCH(R") R^ and R^ is halo, preferably chloro 5 or bromo, most preferably bromo. Such intermediates where R2 is -COC^R^ are prepared from a 1,4-dihalo— 2,3-butane-dione, preferably 1,4-dibromo—2,3—butanedione, by the reaction with an excess of a trialkylorthoformate, preferably triethylorthoformate, in the presence 10 of a catalytic amount of a strong acid, such as concentrated sulfuric acid, p—toluene sulfonic.acid and the like,, at temperature from about 0°C- to about 55°C., preferably from about "15 °C. to about 25°C. The 1,4-dihalo-2,2-dialkoxy-3-butanane produced is 15 then reacted with N-amidinothiourea in an organic solvent, such as tetrahydrofuran, dioxane, ether and the like, at a temperature from about 0°C. to about 55°C.,
"preferably from about 20°C. to 50°C., to form 2-guanidino-4-( 2-halo-l, 1-dialkoxyethyl) thiazole. The 20 latter compound is heated in a hydrogen halide solution, preferably hydrogen bromide, at a temperature from about 0°C. to about 50°C., preferably from about 20°C. to about 3 0°c to form the desired 2-halo—1—{2-guanidino— 4-thiazolyl) ethanone i.e. the intermediate of formula 25 IX, wherein R2 is -COCH2R3 and is halo, preferably bromo. Similarly, compounds of formula II wherein R2 is -COCH(CH3)R3 may be prepared by the reaction of a l-halo-2,3-pentanedione with N-amidinothiourea, as previously described, to form l—( 2-guanidino—4—thiazolyl) 30 propanone, which is then reacted with a halogen in aqueous hydrogen halide solution, preferably with bromine in aqueous hydrobromic acid solution, to give the desired intermediates of formula II.
(
The compounds of formula I wherein. Y is CH or C.CH^ and X is S arc prepared directly from an appropriate 2-halo-l-(2-guanidino-4-thiazolyl)alkanone intermediate of formula II by reaction with an appro-5 priate compound of the formula RCfSJNH^. For example, reaction of the intermediate 2-halo-l-l2-guanidino-4-thiazolyl)-ethanone with a thiourea or a N-R^-substituted-thiourea yields compounds of formula I wherein Y is CH, X is S and R is NHR^, while reaction with thio-10 fcrmamide provides the compound of formula I wherein
Y is CH, X is S and R is hydrogen- The reaction of the 2-halo-l-(2-guanidino-4-thiazolyl)alkanone with the appropriate compound of formula RC(S)NK2 is generally conducted at a temperature from about 0°C. to about
3G°C., preferably from about 20°C. to 30°C., in an inert solvent such as dimethylformamide or other polar organic solvents.
Alternatively, the compounds of formula I wherein
Y is C.CH^ and X is S may be prepared by reaction of a 20 4-halo-2,3-pentanedione, preferably 4-bromo-2,3-
pentanedione, with an appropriate thioamide of the formula RC(S)NH2 to form a 2-R-4-acetyl-5-methyl-thiazole. These intermediates may be halogenated to the 2—halo— l-(2-R-5-methyl-4-thiazolyl) ethanones, which in turn 25 may be reacted with N-amidinothiourea to afford compounds of formula I where Y is C.CH^ and X is S.
Alternatively, compounds of formula I wherein Y is CH, or C.CH'-j, X is S and R is —NHR^ where R^ is alkyl or aralkyl may also be prepared by reaction of the 30 corresponding compounds of formula X wherein R is -NH2
with an alkyl or aralkyl halide in the presence of a
»
base. Similarly, the compounds of formula I wherein
Y is CH or C.CH3/ x is S and R is -NHCORj, may be prepared by the reaction of the corresponding compound
0f formula I wherein R is -NH^ by reaction with an appropriate carboxylic acid halide or anhydride.
Compounds of formula I wherein Y is CH or C.CH^ and X is NH nay also be prepared from the previously described 2-halo-l-(2-guanidino-4-thiazoly1}alkanone intermediates by first forming the corresponding 2-azido-1-( 2-guanidino-4-thiazolyl)alkanone i.e. the novel intermediate of formula II wherein R2 is -COCH(R" )R3 and R^ is N^. The latter compound is formed by the reaction of the 2-halo-l-(2-guanidino-4-thiazolyl)alkanone with an alkali metal azide, such as sodium or potassium azide, in a polar organic solvent such as dimethylformamide or other N,N-diaIky1amides at a temperature from about 0°C. to about 100°C., preferably from about 60°C. to about 100°C., followed by addition of a base such as an alkali metal hydroxide c-r an alkali metal carbonate, preferably sodium or potassium carbonate.
For the preparation of compounds of formula I wherein Y is CH or C.CH^, X is NH and R is ~NH2 or
, the 2-azido-l-( 2-guanidino-4-thiazolyl) ethanone is first reduced to the corresponding 2-amino compound i.e. the novel intermediate of formula II wherein R2 is —COCH(R")and R^ is -NH2/ fox example by hydrogenation in the presence of a noble metal catalyst, such as palladium on carbon, or platinum oxide, in an aqueous lower alkyl alcohol solvent, preferably aqueous methanol or ethanol, in the presence of a strong acid, such as concentrated hydrochloric acid, sulfuric acid, p-toluene sulfonic acid and the like, at a temperature from about 15°C. to about 50°C., preferably from about 20°C. to about 35°C. The 2— amino-1-(2-guanidino-4-thiazolyl)alkanone is then reacted with an appropriate cyanamide of the formula H2NCN or R^NHCN, followed by the addition
of a base such as an alkali metal hydroxide or carbonate, preferably sodium or potassium carbonate, to provide compounds of formula I wherein Y is CH or C.CH^, X is NH and R is -NH2 or —NHR^, respectively.
The N-substituted cyanamides, R^NHCN, used in this reaction can be readily prepared by reaction of the corresponding substituted amine with a cyanogen halide, such as cyanogen bromide or chloride. The reaction of the 2-amino-l-(2-guanidino-4-thiazolyl)alkanone with 10 cyanamide or the appropriate N-substituted cyanamide of the formula R^NHCN is generally effected at a temperature from about 15°C. to about 100°C., preferably from about 70°C. to about 100°C., in aqueous solution, at a pH between about 4 and 5, preferably about 4.5. 15 Alternatively, compounds of formula I wherein Y is
CH or C.CH^, X is NH and R is -NHR^ where R-^ is alkyl or aralkyl may also be prepared from the corresponding compounds of formula I wherein R is -NH2 by reaction with an alkyl or aralkyl halide in the presence of a base.
.20 Further, the compounds of formula I wherein Y is CH or C.CH^, X is NH and R is -NH2 may be reacted with an appropriate carboxylic acid halide or anhydride to form the corresponding compounds of formula I wherein R is -NHCOR^.
Compounds of formula I wherein Y is CH or C.CH^,
X is NH and R is hydrogen, hydroxymethyl, alkyl or ~^CH2^nAr are PrePare<3 from the 2-amino-l-(2-guanidino-4^-thiazolyl)alkanone by reaction with an alkyl carboximidate of the formula RC(NH)ORg, where Rg is alkyl of 1 to 3 30 carbon atoms, preferably methyl or ethyl, or an acid addition salt thereof, for example the hydrogen halide salt, preferably the hydrochloride or hydrobromide salt. The reaction is generally conducted in a lower alkyl
1 ■207253
alcohol solvent, preferably methanol or ethanol, at a temperature from about 0°C. to 70°C. The compound so formed is then converted to the desired compound of formula I wherein Y is CK, X is NH and R is 5 hydrogen or alkyl by heating in the presence of an acid, such as hydrochloric acid, sulfuric acid, p-toluene sulfonic acid and the like, followed by the addition of a base such as an alkali metal hydroxide or carbonate, preferably sodium or 10 potassium carbonate. Alternatively, the 2-azido-l- ;
(2-guanidino-4-thiazolyl)alkanone may be reacted with a trialkylorthoformate to form the corresponding 1,1— dialkoxy derivative, which is then reduced to the ' 2-amino compound and reacted with an alkyl carboximidate, 15 as previously described.
The compounds of formula I wherein Y is N and X is NH may be prepared from 2-guanidino-4-thiazole carboxylic acid hydrazide i.e. the novel intermediate of formula II wherein R2 is -CONHR^ and R^ is -NH2. 20 This intermediate is prepared by the reaction of an alkyl halopyruvate, preferably ethyl bromopyruvate, with N-amidinothiourea in an organic solvent, such as a lower alkyl alcohol of 1 to 4 carbon atoms, preferably methanol or ethanol, at a temperature 25 from about 0°C. to about 100°C., preferably at the reflux temperature of alcohol solvent, to form a 2-guanidino-4-thiazole carboxylic acid alkyl ester. The latter is then reacted with hydrazine in a lower
alcohol solvent, preferably absolute ethanol, at a temperature from about 0°C. to about 100°C., preferably at the reflux temperature of the alcohol solvent, to form the desired 2-guanidino-4-thiazole carboxylic 5 acid hydrazide.
The hydrazide derivative formed as described above is reacted with an alkyl carboximidate of the formula RC(NH)ORg, where Rg is alkyl of 1 to 3 carbon atoms, preferably methyl or ethyl, or an acid addition 10 salt thereof, preferably a hydrohalide such as the hydrochloride or hydrobromide salt, to form the corresponding 2-guanidino-4-thiazole carboxylic acid 2-carboximinohydrazide. The reaction is conducted in an inert organic solvent, preferably a lower alkyl 15. alcohol, such as methanol or ethanol, in the presence of a base, such as an alkali metal alkoxide, preferably sodium or potassium ethoxide, at a temperature from about 10°C. to about 100°C., preferably from about 2 0°C. to 75°C. The 2-guanidino-4-carboxylic acid 20 2-carboximinohydrazide is then heated at a temperature from about 75°C., to about 110°C., preferably from about 90°C. to 100°C., in concentrated ammonia solution to form the desired compound of formula I wherein Y is N and X is NH.
The compounds of formula I wherein Y is N, ■
X is NH and R is -NH2 may be formed from the 2-guanidino-4-thiazole carboxylic acid hydrazide previously described by reaction with 2-methylthiopseudourea H2NC(SCH3)NH, or an acid addition salt thereof, such 30 as the hydrohalide, preferably the hydrochloride or hydrobromide, or the hemisulfate, to form 2-guanidino-4-thiazole carboxylic acid 2-amidinohydrazide i.e. the novel intermediate of formula II wherein R2 is
■ / y/ ^ Q
v, (j <t> Q
-CONHR^ and is -NHC(NH)NH2 - The reaction is generally conducted in an organic solvent such as dimethylsulfoxide at a temperature from about 150°C. to about 225°C., preferably about 180°C. to about 2 00°C. The product is then heated at a temperature from about 75°C. to about 110°C., preferably about 90°C. to about 100°C., in concentrated ammonia solution to form the desired compound of formula I wherein Y is N, X is NH and R is -NH2.
The compounds of formula I where Y is N, X is N3 and R is -NH2 may be reacted with an appropriate alkyl or aralkyl halide in the presence of a base to form the corresponding compounds of formula I wherein R is -NHRj where R^ is alkyl or aralkyl- Similarly,
such compounds where R is -NH2 may be converted to the corresponding compounds where R is -NHCOR^ by reaction with an appropriate carboxylic acid halide or anhydride.
An alternative method of preparing the compounds of formula I wherein R is hydrogen, alkyl or (CH2)nAr is by the reaction of an intermediate of the formula wherein R' is hydrogen, hydroxymethyl, alkyl or -(CH2)nAr, where n and Ar are as previously defined, and R,- is halo, with N-amidinothiourea in an organic solvent such as tetrahydrofuran, ether, a lower alkyl alcohol such as methanol or ethanol and the like at a temperature from about 0°C. to about 75°C. This method of preparation is of particular interest for
0
R
IV
the preparation of compounds of formula I wherein X is NH and Y is CH or C.CH^. The intermediates of formula IV wherein X is NH and Y is CH or C.CH^ (i.e. the compounds of formula III as previously described) 5 may be prepared by halogenation of the corresponding f
2-R -5-R"-4-acety1-imidazole where R" is hydrogen or methyl, for example by reaction with a halogen in ah aqueous hydrogen halide solution, preferably with bromine in aqueous hydrobromic acid.
I
. The 2-R -5-R"-4-acety1 imidazole for use in this reaction may be prepared by irradiation of 1-acetyl-
I
2-R -5-R"-imidazole with ultra-violet light. Alterna-
I
tively, 2-R -4-acetyl-imidazoles may be prepared by reaction of a 3-halo-4-n-alkoxy-3-buten-2-one, especially 15 the 3-chloro- or 3-bromo- compound, with an appropriate R -substituted amidine of the formula R C(NH2)MH or a salt thereof in the presence of a base such as a trialkylamine, preferably triethylamine, in an organic solvent such as acetone, tetrahydrofuran, dioxane and 20 the like, at a temperature from about 0°C. to about
100°C., preferably at reflux temperature in tetrahydrofuran .
The 3-halo-4-n-alkoxy-3-buten-2-one starting materials may be prepared from the known 3-halo-4-25 hyaroxy-3-buten-2-one by reaction with a dialkylsulfate or diazoalkane in, for example, aqueous tetrahydrofuran or dioxane, in the presence of a weak base such as an alkali metal bicarbonate at a temperature from about 0°C. to about 60°C. , preferably from about 15°C. to 30 3C°C- Alternatively, the 3-halo-4-n-alko>y-3-buten-2-one may be prepared by heating a 3-halo-4—hydroxy-3-buten—
»
2-one at reflux with an appropriate n-alkanol, for example in toluene solution.
' . ■ f,0725^
The preparation of corresponding intermediates of formula IV for the preparation of other compounds of formula I i.e. having other X and Y groups, may be prepared by reactions analogous to those described 5 hereinabove by the use of appropriately substituted starting materials.
The pharmaceutically acceptable acid addition salts of the novel compounds of formula I are also embraced by the present invention. The salts are 10 readily prepared by contacting the free base with an appropriate mineral or organic acid in either aqueous solution or in a suitable organic solvent. The solid salt may then be obtained by precipitation, or bv evaporation of the solvent. The pharmaceutical ly 15 acceptable acid addition, salts of this invention include, but are not limited to, the hydrochloride, sulfate, bisulfate, mesylate, nitrate, phosphate, acetate, lactate, maleate, fumarate. citrate,
tartrate, succinate, gluconate and the like. Pre— 20 ferred salts are the hydrochloride and dihydrochloride. If desired, the compounds of formula I as the free base may be formed from the acid addition salts thereof by treatment with an appropriate base followed by extraction of the free base with a suitable organic 25 solvent.
The compounds of formula I and the pharmaceutical ly acceptable acid addition salts thereof have activity as antisecretory agents and histamine antagonists and acccordingly are of therapeutic value in the 30 treatment of gastric hyperacidity and peptic ulcers. For the purposes of the present specification and claims hereof the term treatment of gastric hyperacidity is meant to include the treatment of peptic ulcers and other such conditions caused by, or
aggravated, by the secretion of gastric acid. The compounds may be administered to a subject in need of treatment by a variety of conventional routes of administration including orally and parenterally . Preferably, the compounds axe administered orally. In general, these compounds will, be administered orally at doses between about 0.1 and 2 0 mg/kg body weight of the subject to be treated per day,, preferably from about 0.2 to 2.5 ing/kg per day. If parenteral administration is desired,
then these compounds can be given at doses between about 0.1 and 1.0 mg/kg body weight of the subject to be treated per day. However, some variation in dosage will necessarily occur depending upon the cor.dition of the subject being treated and the particular compound employed.
The compound may be administered alone or in combination with pharmaceutically acceptable carriers or diluents, in either single or multiple doses. Suitable pharmaceutical carriers include inert diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the novel cornpounds of formula I or salts thereof and pharmaceutically acceptable carriers are readily administered in a variety of dosage forms such as tablets, powders, capsules, lozenges, syrups and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, exeipients and the like. Thus, for oral administration, tablets containing various excipients, such as sodium citrate, may be employed, together with various disintegrants
such as starch, alginic acic and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. V7hen aqueous suspensions or elixirs are desired for oral administration, the essential active ingxedient therein may be.combined with vaxious sweetening or flavoring agents, coloring matters or dyes.and, if desired, emulsifying agents or suspending agents,
together with diluents such as water, ethanol,
propylene glycol, glycerin, or combinations thereof.
Preferably, the novel compounds of this invention are administered orally in unit dosage form, i.e. as a single physically discrete dosage unit containing an appropriate amount of the active compound in combination with a pharmaceutically acceptable carrier or diluent. Examples of such unit dosage forms axe tablets or capsules containing from about 5 to 1,000 mg of the active ingredient, the compound of formula I comprising from about 10% to 90% of the total weight of the dosage unit.
For. parenteral administration, solutions of the compounds of formula I in sterile aqueous solutions, for example aqueous propylene glycol, sodium chloride, dextrose or sodiupi bicarbonate solutions may be employed. Such solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The preparation of suitable sterile liquid media for parenteral administration will be well known to those skilled in the art.
, 2.07 2 ' -
The activity of the compounds of the present invention as antisecretory agents and histamine-f^ antagonists may be determined by standard pharmacological tests, including for example (1) measuring their ability to antagonize the actions of histamine which are not blocked by an antihistamine such as mepyramine and (2) measuring their ability to inhibit gastric acid secretion in the stomachs of Heidenhain pouch dogs that had previously been treated with pentagastrin in order to stimulate the secretion of gastric acid.
All temperatures in the following examples are in degrees centigrade.
Example 1 1,4-Dibromo-2,2-diethoxy-3-butanone A mixture of 40 g (0.164 mol) of 1,4-dibromo—2,3-butanedione, 60 ml (0.36M) of triethylorthoformate, and 2 ml of concentrated sulfuric acid was stirred at room temperature for 14 hours, then diluted with 600 ml of chloroform, and washed successively with 100 ml portions of water, 0.5N hydrochloric acid and saturated sodium chloride solution. The organic solution was dried over anhydrous sodium sulfate filtered, and evaporated leaving an oil- The oil was taken up into 3 00 ml of hexane and filtered to remove some insoluble material. The hexane filtrate was cooled in a dry-ice/acetone bath, and the resulting precipitate was collected by filtration and dried to give 44 g (84%) of' 1,4-dibromo-2,2-diethoxy—3—
butanone as a white crystalline solid, mp 40-41.5°; nmr (CDC13) (/): 4.50 (s, 2H); 3.6-3.2 (m, 6H); 1.22 (t, 6H).
Exar.ipLe 2
2-Guanidicio--i- ( 2-bromo-l, 1 -Uiethoxyethyl.) thiazolh--
A mixture of 25.5 g (30 n:rnol) of 1,4—dibronc-2,2-dierhoxv-3-butanone, 11.8 g (100 mmol) of N-amidinothiourea, and 150 nl of tetrahydrofuran was heated at reflux for 3 hours. The mixture was filtered to remove some insoluble solid, and the filtrate was concentrated. The residue was triturated with 200 ml of saturated sodium bicarbonate, then extracted four times with a total of 500 ml of ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulfate,
filtered and evaporated leaving a solid. Recrystalliza-tion from 2 50 ml of acetonitrile, after decolorization with charcoal, afforded 9.7 g (36%) of 2-guanidino-' 4-(2-bromo-l,1-diethoxyethyl)thiazole as a white solid, mp 157-158°; calcd. for C^H^I^C^SBr: C, 35.62; K, 5.08; N, 16.61; Br, 23.69; S, 9.51;
found: C, 35.60; H, 4.97; N, 16.99; Br, 23.75; S,
9.59.
Example 3
2-Bromo-l-(2-guanidino-4-thiazolyl)ethanone hydrobromide
A mixture of 9.5 g (28 mmol) of 2-guanidino-4-(2-bromo-l,1-diethoxyethyl)thiazole in 50 ml of 48% hydrobromic acid was stirred at room temperature for 15 hours. The mixture was evaporated to complete dryness to afford 10.1 g (100%) of 2-bromo-l-(2— guanidino-4-thiazoly1)ethanone hydrobromide mp 247° (dec) . This material could be converted to the free base by triturating with saturated sodium bicarbonate, stirring for 15 minutes, filtering the solid, and drying it under vacuum. In this way, 3.0 g of the hydrobromide
salt was converted to 1.7 g (83%)-of the free base, mo 210° (dec); nmr (DMSO-dg ): 7.84 (s, IK); 5.92 (s, 4H); 4.7 8 (s, 2H).
Example 4
2-Guanidino-4-(2-araino-4-thiazoly1)thiazole dihydrobromide
A' solution :of 688 mg f 2.0 mmol)' of 2'-brorio-l-: ( 2-guanidino-4-thiazolyl)ethanone hydrobromide and 183 mg of thiourea in 5 ml of diroethylformamide was stirred at room temperature. After a short time, a solid began to precipitate. After a total of four hours, the solid was collected by filtration, washed with ethyl acetate, and dried, thereby affording 595 mg (7 4.%) of 2-guanidino-4-(2-amino-4-thiazolyl)thiazole dihydrobromide as a white powder; mp 320° (dec); mass spectrum parent of 240. This material could be converted to its free base by triturating with saturated sodium bicarbonate solution, stirring for 15 minutes, filtering the solid, and drying it under vacuum. In this way 2-guanidino-4-(2-amino-4-thiazolyl)thiazole was obtained as a crystalline solid, mp 274°. Calcd. for C7HgN6S2: C, 34.99; H, 3.36; N, 34.97;
found: C, 34.94; H, 3.41; N, 34.80.
Example 5 2-Guanidino-4-(4-thiazolyl)thiazole A mixture of 1.8 g (5.2 mmol) of 2-bromo-l-(2— guanidino-4-thiazolyl)ethanone hydrobromide, 0.34 g (5.5 mmol) of thioformamide, and 10 ml of dimethyl-formamide was stirred at room temperature for 2 hours. The mixture was concentrated and the residue was triturated with acetonitrile. The resulting precipitate was collected by filtration, washed with acetonitrile,' and dried to afford 1.74 g (85%) of
r,> <f*
/r- %■!/
7 2 5
2-guanidino-4-(4-thiazoly1)thiazole dihydrobromide.
This was dissolved in 10 ml of wat?r, and 1 ml of saturated sodium bicarbonate solution was added -The resulting precipitate was collected by filtration, 5 washed well with water, then acetonitrile, then dried in vacuo to afford 1.17 g of 2-guanidino-4-(4-thiazoyl)thiazole as a white solid, mp 220-222°; ■nmr (DMSO-dg) (/): 8.96 (s, 1H); 7.96 (s, 1H); 7.18 (s, 1H); 7.0 (b, 4H);
calcd. for C7H7N5S2: C, 37.32; H, 3.13; N, 31.09;
found: 36.94; H, 3.52.; N, 29.74.
Example 6
2-Guanidino-4-(2-N-methylamino-4-thiazoyl)thiazole
A mixture of 1.77 g (5.14 mmol) of 2-bromo-l-(2-15 guanidino-4-thiazoyl)ethanone hydrobromide, 0.49 g
(5.5 mmol) of N-methylthiourea, and 10 ml of dimethyl-formamide was stirred at room temperature for 12 hours. The mixture was concentrated and the residue was triturated with a small amount of acetonitrile. The 20 crude solid was collected by filtration, then dissolved in water. The aqueous solution was made basic with saturated sodium bicarbonate solution and the resulting precipitate was collected by filtration and allowed to dry. Recrystallization from ethanol/water afforded 25 0.70 g (54%) of 2-guanidino-4-(2-N-methylamino-4-thiazoyl)thiazole as a white solid, mp 267°; nmr (DMSO-dg) (/): 7.44 (q, 1H); 7.0-6.9 (s+s+b, 6H); 2.85 (t, 3H); calcd. for CgH-^QNgS2: C, 37.77; II, 3.96; N, 33.05; found: C, 38.01; H, 4.47: N, 32.84.
Examp.ie 7
2-Guanidino-4- ( 2-M-acetylarr.ino-4-th.io.2oyI ) thiazole
A mixture of 1.77 g (5.14 mmol) of 2-bromo-l-
( 2-guanidino-4-thiazoyl)ethanone hydrobromide/ 0.65 g
(5.5 mmol) of N-acetylthiourea, and 10 ml of dimethyl-
formamide was stirred at room temperature for 13 hours.
The mixture was concentrated and the residue triturated with acetonitrile. The resulting solid was collected by filtration, then added to 50 ml of saturated sodium
bicarbonate solution and stirred for 1 hour. The solid was collected by filtration and allowed to dry. Re-
crystallization from ethanol/water afforded 1.0 g
(68%) of 2-guanidino-4-(2-N-acetylamino-4-thiazoyl)-
thiazole as a white solid, mp 288°; nrnr (DMS0-d^) {£ ):
6
7.40 (s, 1H); 7.0-6.9 (b, 5h); 3.2 (b, 1H); 2.22 (s, 3H); calcd. for CgH10NgOS2: C, 38. 28; H, 3.57; N, 29.77; found: C, 38.13; H, 4.07; N, 29.41.
Example 8
2-Guanidino-4-thiazole carboxylic acid ethyl ester 20 111.2 g (0.94 mol) of 2-amidinothiourea was dissolved in 1 liter of refluxing ethanol. To the refluxing solution was rapidly added over a 10 minute period 2 00 g (1.02 mol) of ethyl bromopyruvate. After 2 hours of reflux an additional 20 g (0.1 mol) of ethyl 25 bromopyruvate was added and reflux was continued for an additional 2 hours. The reaction was cooled to 10° and concentrated ammonium hydroxide solution was added to raise the pH to 10. A solid formed and was collected by filtration, washed twice with ether 30 and dried in vacuo to give 176.4 g (88%) of 2—
guanidino—4-thiazole carboxylic acid ethyl ester, mp 229-230°(dec.)
Example 9
2-Guanidino-4-thiazole carboxylic acid hydrazide 16.7 g (0.077S mol) of 2-guanidino-4-thiazole carboxylic acid ethyl ester was combined with 25 ml {0.514 mol) of hydrazine hydrate in 200 ml absolute ethanol. The slurry was heated to.reflux.. . After 1.5 hour reflux a solid began to form from the clear solution. After 2 hours reflux the reaction slurry was cooled and the resulting solid was collected by filtration and was washed with isopropyl alcohol and ether to give 12.8 g (82%) 2 guanidino—4-thiazole carboxylic acid hydrazide, mp 247° (dec.).
Example 10 2-Guanidino-4-thiazole carboxylic acid 2-amidinohydrazide hemisulfate 17.9 g (0.0 89 mol) of 2 guanidino-4-chiazole carboxylic acid hydrazide was combined with 24.5 g of 2-methyl-2-thiopseudourea sulfate (0.089 mol)
and heated rapidly to reflux in 125 ml diraethyl-sulfoxide. The reactants dissolved and within 5 minutes reflux a heavy precipitate formed. Reflux was continued for a total of.3 0 minutes. The reaction was cooled and the resulting heavy precipitate was isolated by filtration and washed with a small portion of dimethyl sulfoxide followed by washing with isopropyl alcohol and ether. The resulting solid was dried in vacuo to give 3 4.6 g of 2-guanidino-4-thiazole carboxylic acid 2-amidinohydrazide containing some occluded dimethylsulfoxide.
Example 11
2-Guanidino-4-(3-amino-5-l,2,4-triazolyl)thiazole 29.1 g (0.1'mol) of 2-guanidino-4-thiazole carboxylic acid 2-amidino hydrazide hemisulfate was heated to boiling with 250 ml concentrated ammonium hydroxide. Additional ammonium hydroxide was added
i to replace the volume lost due to loss of ammonia.
After 8 hours heating, boiling was continued until the pH was below 8.0 and the mixture was allowed to cool. The resulting solid was collected by filtration, 5 washed with a small portion of water, decolorized with charcoal, recrystal 1 ized from water and dried i_n vacuo to give 10.8 g (48%) of 2-guanidino-4-(3-amino-5-l,2,4-triazolyl)thiazole, mp 173-5°. nmr (DMSO-Dg) (/ ): 7.07 (s, 1H); 6.93 (broad s, 4H); 5.53 (broad s, 2H); 10 Calcd. for CgHgNgS: C, 32.14; H, 3.60; N, 49.97;
found: C, 32.13; H, 3.70; N, 50.15.
Example 12 2-Guanidino-4-thiazole carboxylic acid 2-acetiminohydrazide 15 37.1 g (0.3 mol) of ethyl acetimidate hydro chloride was dissolved in 200 ml absolute ethanol. A solution of sodium ethoxide (6.9 g (0.3 mol) sodium in 300 ml absolute ethanol) was added. The resulting precipitate, of sodium chloride was removed by fil-20 traticn and to the clear filtrate was added 20.0 g (0.1 mol) of 2-guanidino-4-thiazole carboxylic acid hydrazide. The slurry was stirred at 25° for 6 0 hours, during which time complete dissolution occurred. The clear, pale orange solution was 25 concentrated in vacuo to a soft solid which was triturated in 10:1 ethyl acetate-ethanol to give 24.0 g (88%) of crude 2-guanidino-4-thiazole carboxylic acid 2-acetiminohydrazide, with a broad melting point, 150° to 178° (dec.) .
Example 13
2-Guanidino-4-(3-methyl—5-1,2,4-triazolyl)thiazole hemihydrate 23.0 g (0.095 mol) of 2-guanidino-4-thiazole carboxylic acid 2-acetiminohydrazide was heated to
boiling with 200 ml concentratod ammonium hydroxide solution. Additional ammonium hydroxide was added to replace the volume lost due to loss of ammonia. After 7 hours heating, boiling was continued until the pH was below 8.0 and the mixture was allowed to cool. The resulting solid was collected by filtration, washed with a small portion of water and then dried (110°/0.1 mm Hg) for 24 hours to give 8.6 g (39%) 2-guanidino-4-(3-methy1-5-1,2,4-triazolyl} thiazole hemihydrate mp 185° (loss of H20), 260° (dec.), nmr (DMSO-dg) (/).- 7.22 (s, IK); 6.90 (broad s, 4H) , 3.50 (broad s, 1H-H20); 2.32 (s, 3H); Calcd. for C7H9N7S.l/2 E20: C, 36.19; H, 4.34; N, 42.22; found: C, 36.43; H, 4.29; N, 42.17.
Example 14 2-Guanidir.o-4-thiazole carboxylic acid 2-butyriminohydrazide 2.90.g (14.4 8 mol) of 2-guanidino—4-thiazole carboxylic acid hydrazide in 50 ml dry ethanol was slurried with 29.1 mmol of ethyl butyrimidate (prepared from 4.41 g (29.1 mmol) .of ethylbutyrimidate hydrochloride) for 5 days at 25°. The slurry was filtered and washed with ethanol and ether and dried to give 3.0 71 g (78%) of 2-guanidino-4-thiazole carboxylic acid 2-butyriminohydrazide.
Example 15 2-Guanidino-4-(3-propyl-5— 1,2,4-triazolyl)thiazole hemihydrate 2.547 g (9.5 mmol) of 2-guanidino-4-thiazole carboxylic acid 2-butyriminohydrazide was heated at reflux in 5 0 ml water for 2 hours. The reaction was cooled and the resultant solid was recrystallized
frorr. 150 ml of a 4:.l water: ethanol solution to give 1.119 g (47%) of 2-guanidino--1-( 3-propyI-5-l, 2, 4-triazolyl)thiazole hemihydrate, mp 268-270° (dec.), nmr (DMSO-dg) (/ ): 13.68 (broad s, 1H); 7.18 (s, 1H) ;
6.90 (broad s, 4H); 2.64 (t, 2H); 1.70 (m, 2H);
0.90 (t, 3K); Calcd. for C9H13N7S.1/2H20: C, 41.52; H, 5.42; N, 37.66; found: C, 41.81; H, 5.50;
N, 38.10.
Example 16
2-Guanidino-4-thiazole carboxylic acid-
2-propioniminohydra2ide 2.90 g (14.48 mmol) of 2-guanidinc-4-thiazole carboxylic acid hydrazide in 50 ml dry ethanol was slurried with 29.1 mmol of ethyl propionirr.idate 15 (prepared from 4.0 g (29.1 mmol) of ethyl propionimiaate hydrochloride) for 5 days at 25°. The slurry was filtered and the resulting solid was dried for 2 hours at 60° in vacuo to give 2.802 g (75%) of 2-guanidino-4-thiazole carboxylic acid 2-propioniminohydrazide. 20 Example 17
2-Guanidino-4-(3-ethyl-5-1, 24-triazolyl)thiazole 2.72 6 g (10.7 mmol) of 2-guanidino-4-thiazole carboxylic acid 2-propioniminohydrazide was heated at reflux in 50 ml water for 2 hours. On cooling a 25 solid precipitated. This was treated with 200 ml boiling water, a small quantity of insoluble material was removed and the solution was cooled to afford a white solid. Two additional recrystallizations from water gave 1.04 8 g (41%) of 2-guanidino-4-(3-ethyl-5-30 1,2,4-triazolyl)thiazole, mp 251-7° (dec.). nmr
(DMSO-dg) (/ ): 13.80 (broad s, 1H); 7.27 (s,lH); 6.95 (broad s, 4H); 2.7 0 (q, 211); 1.25 (t, 3H) ;
Calcd. for C8h1]ln7S: C, 40. 49; H, 4.67; N, 41.32; found: C, 40.61; H, 4.60; N, 40.50.
Example 18
2-Azido-l-(2-guanidino-4-thiazolyl)ethanone A mixture of 50 g (0.14 mol) of 2—bromo—1-{2-guanidino-4-thiazolyl)ethanone hydrobromide, 23.6 g 5 ( .36 mol) of sodium azide, and 250 ml of dimethyl-
formamide was stirred at room temperature for 1.5 hours. The mixture was poured into 1.5 liters of water, and the aqueous solution was made basic with solid sodium carbonate. The resulting precipitate was filtered, 10 washed well with water, and dried, thereby affording 30.6 g (93%) of 2-azido-l-(2-guanidino—4-thiazolyl)-ethanone as a light brown crystalline solid, mp 177° (dec). Analytically pure material can be prepared by recrystallization from absolute ethanol: Calcd. for 15 C6H7N7OS: C; 32.00; H, 3.13; N, 43.53; S. 14.24;
.fc'und: C, 32.22; H, 3.43; N, 41.93; S, 13.97.
Example 19
2-Amino-l-(2-quanidino-4-thiazolyl)ethanone.dihydrochloride A mixture of 12.0 g (53 mmol) of 2-azido-l-(2-20 guanidino-4-thiazolyl)ethanone, 1.0 g of 10% palladium on carbon, 100 ml of ethanol, 50 ml of water, and 2 0 ml of concentrated hydrochloric acid was hydrogenated at 3 atm. and. room temperature for 1 hour- At this point another 50 ml of water and 300 mg of 10% 25 palladium on carbon was added to the mixture and hydrogenation was continued at 3 atm for another 0.75 hour. The mixture was diluted with 200 ml of water, filtered to remove the catalyst, and the filtrate concentrated leaving 13.1 g (92%) of 2-amino-l-(2-30 guanidino-4-thiazolyl)ethanone dihydrochloride as a white powder mp> 270°. nmr (DMSO-dg) (<f) : 8.58 (b, 4H) 8.44 (s, l'H); 4.58 (b, 4H).
Example 20
2-Guanidino-4- ( 2-ammo-4-imidazolyl) thiazole A mixture of 43 g (0.15 mol) of 2-a;aino-l-(2-guanidino~4-thiazoly1)ethanone dihydrochlorde, 5 12.6 g (0,30 mol) of cyanamide, and 4 00 ml of water was brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was heated at 50-6 0° for 16 hours. The mixture was cooled, made basic with aqueous sodium carbonate solu— 10 tion and the resulting precipitate was collected by filtration, then washed successively with cold water, acetone, and ether. The dried solid was purified by dissolving . in a minimum of dimethylformamide,
then slowly adding ethyl acetate. Initially tarry 15 naterial precipitated which was removed by decanting. Further addition of ethyl acetate afforded 16 g of a tan solid. This was again purified by the dimethyl-form amide- ethyl acetate procedure described above to give 12 g; of a tan solid. Recrystallization of this
2 0 material from methanol/water afforded analytically pure title compound as tan needles, mp 267° (dec). Calcd. for C7HgN?S: C, 37.66; H, 4.06; N, 43.91; S, 14.36; found: C, 37.81; H, 4.31; N, 43.76.
Example 21
2-Guanidino-4-(2-N-methylamino-4-
imidazoyl)thiazole dihydrochloride A mixture of 2.0 g (7.3 mmol) of 2-aniino—1-(2-guanidino-4-thiazoly1)ethanone dihydrochlorider 0.62 g (11 mmol) of N-methylcyanamide, and 10 ml of
3 0 water was brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was
heated at 50° for 16 hours. The mixture was cooled,
made basic with aqueous sodium carbonate solution and the resulting precipitate was collected by filtration, then washed successively with cold water, acetone, and acetonitrile. The crude solid was converted to its dihydrochloride salt by dissolving it in a minimum amount of saturated methanolic hydrogen chloride, then slowly adding ethsr. Initially tar precipitated and this was removed by decanting.
Further addition of ether resulted in the precipitation cf a crystalline solid which was filtered and dried. Recrys tallization from methanol/ether afford 190 mg (10%) of the pure title compound, mp 280°; nmr (DMSO-dg) (/ ): (free base) 6.86 (b, 5H); 6.77 (s, 1H); 6.45 (3, 1H); 5.60 (b) (1H): 2.68 (d, 3H); calcd. for CgH11N7S.2HCl.H20: C, 29.27; H, 4.61; N, 29.87;
found: C, 30.01; H, 4.81; N, 29.78.
Example 22 2-Guanidino-4-(2-N-ethylamino-4-imidazoyl)thiazole dihydrochloride A mixture of 4.0 g (15 mmol) of 2-amino-l-(2-guanidino-4-thiazolyl)ethanone dihydrochloride, 1.54 g (22 mmol) of N-ethylcyanamide,.and 20 ml of water was brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was heated at 50° for 16 hours. The mixture was cooled, made basic with aqueous sodium carbonate solution and the resulting precipitate was collected by filtration and washed successively with cold water, and acetone. The crude solid was converted to its dihydrochloride salt by dissolving it in a minimum amount of saturated ethanolic hydrogen chloride," filtering away insolubles, then slowly
/7 r~
adding ether. The resulting precipitate was collected by filtration, washed with ether and dried. Re-
crystallization from ethanol/ether afforded 0.46 g
(10%) of the title compound mp 235°; nmr (DMSO-d^)
o
(/ ): 8.42 (b, 5H); 7.99 (t, 1H); 7.87 (s, 1H); 7.65 (s, 1H); 3.43 (m, 2H) ; 1.19 (t, 3H); calcd. for CgK13N7S.2HCl.H20: C, 31.58; H, 4.71; N, 28.65; found: C, 31.11; H, 5.38; N, 27.79.
Example 23 2-Guanidino-4- (2-N-n-propylamino-4—
imidazovl) thiazole dihydrochloride A mixture of 2.0 g (7.3 mmol) of 2-amino—1—(2— gnanidino-4-thiazolyl)ethanone dihydrochloride. 0.92 g (11 mmol) of N-n-propylcyanamide, and 20 ml of water was brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was heated at 50° for 16 hours, then cooled, made basic with aqueous sodium carbonate solution and filtered to remove some insoluble material. The filtrate was concentrated and the residue was triturated with 50 ml of ethanol and filtered to remove insoluble material. Concentration of the filtrate afforded a crude solid which was converted to its dihydrochloride salt by dissolving in saturated ethanolic hydrogen chloride, filtering away some insoluble material, and diluting the filtrate with ether. The resulting precipitate was filtered, washed with ether and dried. F.ecrystal— lizaticn from ethanol/ether afforded 180 mg (7%) of the pure title compound, mp 227-229°; nmr (DMSO-dg) (/): 8.40 (b, 6H); 7.86 (s, 1H); 7.64 (s, 1H); 3.40 (m, 2H); 1.62 (m, 2H) ; 0.09 (t, 3H); calcd. for
C10H15N7S*2HC1 *H2°': C' 33-71' H' 5.38; N, 27-52;
found: C, 33.75; H, 5.03; N, 26-41.
20725
Exanple 24 2-Guanidino-4-(2-N-i-propylamino-4-imidazoyl)thiazole dihydrochloride A mixture of 2.0 g (7.3 mmol) of 2-amino-l-5 ( 2-guanidino-4-thiazolyl)ethanone dihydrochloride,
0.92 g (11 mmol) of N-_i-propylcyanamide, and 20 ml of water was brought to pH 4.5 by the dropwise addition of 2 0% sodium hydroxide solution. The mixture was heated at 60° for 16 hours. Another 0.30 g (3.7 mmol) 10 of N-_i-propyl cyanamide was added and the mixture was heated at 110° for 3 hours. The mixture was made basic with aqueous sodium carbonate solution and filtered to remove some insoluble material. The filtrate was concentrated and the residue was triturated wth 50 ml 15 of ethanol ana filtered to remove inorganics. Concentration of the filtrate afforded a crude solid which was converted to its dihydrochloride salt by dissolving in saturated ethanolic hydrogen chloride, filtering away insoluble material, and diluting the filtrate with 20 ether. The resulting precipitate was filtered, washed with ether and dried. Recrystallization from ethanol/ ether afforded 0.3 4 g (13%) of the pure title compound, mp 138°; nmr (DMSO-dg) ( / )-. 8.39 (b, 6H) ; 7.82 (s, 1H) ; 7.59 (s, 1H); 3.10 (m, 1H) ; 1.05 (d, 6H)-. calcd. for 25 C1qH15N7S.2HC1.H20: C, 33.71; H, 5.38; N, 27.52;
found: C, 33.71; H, 5.97; N, 26.15.
Example 25 2-Guanidino-4-(2-N-n-butylamino-4-imidazoyl)thiazole dihydrochloride 30 A mixture of 2.0 g (7.3 mmol) of 2-amino-l-(2-
guanidino-4-thiaz"oy 1) ethanone dihydrochloride, 1.08 g (11 mmol) of N-n-butylcyanamide; and 20 ml sodium hydroxide solution. The mixture was heated at reflux
ry /> -7-
\w, a
for 6 0 hours, then cooled, made basic with aqueous sodium carbonate solution, then concentrated. The solid residue was triturated with methanol, filtered to remove insolubles, and the filtrate concentrated
leaving an oil. The oil was taken up in 20 ml of ethanolic hydrogen chloride, filtered again to remove insolubles, and the filtrate was diluted with ether-
The resulting precipitate was collected by filtration,
washed with ether, and dried in vacuo to afford 0.25 g
(10%) of 2-quanidino-4-(2-N-n-butylamino-4—imidazoyl)—
thiazole dihydrochloride mp 224-228°; nmr (DMSO-d,)
o
(<f ): 8.40 (b, 6H); 7.82 (s, 1H); 7.60 (s, 1H) ; 3.40 (m, 2H); 1.8-1.3 (m, 4H); 0.97 (t, 3H).
Example 26
2-Guanidino~4-(2-N-benzylamino-4—
imidazoyl)thiazole dihydrochloride A mixture of 2.0 g (7.3 mmol) of 2-amino-l—(2-guanidino-4-thiazolyl) ethanone dihydrochloride, 1.45 g (11 mmol) of N-benzylcyanamide, and 2 0 ml of water was 20 brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was heated at 60° for 16 hours. Another 0.4 8 g (3.7 mmol) of N—benzylcyanamide was added and the mixture was heated at 110° for 20 hours. The mixture was cooled to room temperature, then made 25 basic with aqueous sodium carbonate. The resulting precipitate was collected by filtration, washed with water, and allowed to dry. The solid was stirred in 6 0 ml of methanol, filtered to remove insolubles, and the filtrate concentrated. The residue was taken up 30 into 4 0 ml of ethanolic hydrogen chloride, filtered to remove precipitate amounted to 1.5 g (51%) of the
pure title compound, mp 174°; nmr (DMSO-dg) {£ ): 8.41 (b, 6H); 7.94 (s, 1H); 7.72 (s, 1H); 7.6-7.1 (m, 5H ) ; 4.72 (d, 2H); calcd. for C^H^N^S. 2HC1 . H^O: C, .41.58; H, 4.74; M, 24.25; found: C, 41.97; H, 5.43; N, 2 3.80
Example 27 2-Guanidino-4- ( 2-N-phenethylamino—4—
imidazoyl) thiazole dihydrochloride A mixture of 2.0 g (7.3 mmol) of 2-amino— 1-(2-gnanidino-4-thiazoyl)ethanone dihydrochloride, 1.61 g (11 mmol) of N-phenethyIcyanamide, and 20 ml of water was brought to pH 4.5 by the dropwise addition of 20% sodium hydroxide solution. The mixture was heated at 60° for 16 hours. Another 0.54 g (3.7 mmol) of N— phenethyIcyanamide was added and the mixture was heated at 110° for 2 0 hours. The mixture was cooled to room temperature, then made basic with aqueous sodium carbonate. The resulting precipitate was collected by filtration, washed with water, and allowed to dry. The solid was stirred in 60 ml of methanol, filtered to remove insolubles, and the filtrate concentrated. The residue was taken up into 40 ml of ethanolic hydrogen chloride, filtered to remove insolubles and the filtrate diluted with 2 00 ml of ether. The resulting precipitate amounted to 0.62 g. (20%) of the pure title compound, mp 187°; nmr (DMSO-dg) (/ ): 8.48 (b, 6H) ; 7.94 (s, 1H) ; 7.70 (s, 1H); 7.38 (s, 5H) ; 3.72 (m, 2H) ,- 2.96 (t, 3H): calcd. for C15H17N7S.2HC1,H20: C, 43.06; H, 5.06; N, 23.44; found: C, 42.36; H, 5.13; N, 23.30.
(
Example 28
2-Guanidino-4-(2-N-ace tamido-4-imidazoyl)thiaz o 1 e A mixture of 1.0 g (4.5 mmol) of 2-guanidino-4-(2-amino-4-imidazoyl) thiazole 0.35 (4.5 mmol) of acetyl chloride, and 10 ml of pyridine was stirred at room temperature for 2.5 hours. The supernatant solution was decanted from an insoluble residue and poured into 20 ml of water. This aqueous solution was concentrated and the crude solid residue was triturated with 4 ml of water. The resulting solid was filtered, and dried to give 0.18 g (16%) of the title compound, mp 151-155°; nmr (DMSO-dg): (/ ) 7.38 (s, 1H); 7.2-6.8 (b, 6H); 6.76 (s, 1H) ; 1.97 (s, 3H) . Recrystallization from ethanol/ether afforded analytically pure product; mp 159-160°; calcd. for CgH-^N-yOS-HjO: C, 38.15; H, 4.62; N, 34.60; found: C, 38.09; E, 4.21; N, 34.88.
Example 29 4-Acetylimidazole A mixture of 6.0 g (54 mmol) of 1-acetylimidazole in 50 ml of tetrahydrofuran was photolyzed in a Rayonet reactor using a quartz vessel at 30° for 16 hours. The mixture was concentrated and the residue chromatographed over 100 g of silica gel using 19:1 chloroform/methanol as eluent. The less polar product was 2-acetylimidazole, mp 13 3-135° (0.32 g, 5%). The more polar product amounted to 1.1 g (19%) of 4-acetylimidazole, mp 165-168°.
Example 3 0
2-Bromo-l-(4-imidazoyl)ethanone hydrobromide
A solution of 0.50 g (4.5 mmol) of 4-acetylimidazole in 10 ml of methanol was stirred at room temperature and 10 drops of 48% hydrogen bromide was added. After stirring at room temperature for 15 minutes, 50 ml of
(
absolute ether was added and the resulting precipitate was collected by filtration and dried to give 0.54 g of the hydrobromide salt, mp 214° (dec). This was dissolved in 10 ml of 48% hydrogen bromide, warmed to 60° and 5 0.15 ml (3.0 mmol) of bromine was added. After stirring at 60 ° for 1 hour , the mixture, was concentrated and the residue triturated with a mixture of isopropanol/ether. The white crystalline precipitate was filtered, washed with ether, and dried to give 0-42 g 10 (35%) of 2-bromo-l-(4-imidazoyl)ethanone hydrobromide, mp 188°-192°. nmr (DMSO-dg) (/ ): ,9.02 (s, 1H); 8.45 (s, 1H); 4.84 (s, 2H).
Example 31 ■
2-Guanidino-4-(4-imidazoyl)thiazole hydrobromide 15 A mixture of 0.38 g (1.4 mmol) of 2-bromo-l—(4-
inidazoyl)ethanone hydrobromide in 10 ml of acetone was warmed until homogeneous, then 0.17 g (1.4 mmol) of amidinothiourea was added and the mixture was heated at reflux for 0.5 hour. The mixture was 20 cooled and the white precipitate was collected,
washed with ether, and dried, thereby affording 0.24 g (60%) of 2-guanidino-4-(4-imidazoyl)thiazole hydrobromide, mp 225° (dec). nmr (DMSO-dg) (& ) : 8.20 (s, 1H); 8.0 (b, 4H); 7.77 (s, 1H); 7.36 (s, 1H); 25 high resolution mass spectrum: calcd. C^HgNgS: for
208.C531; found: 208.0517; calcd. for C^HgNgS.HBr.I^O: C, 27.37; H, 3.60; N, 27.36; found: C, 27.23; H, 3.57; N, 27.64.
Example 3 2 2-Guanidino-4- ( 4-imidazoyl ) r.hiazole A mixture of 42 ml of concentrated sulfuric acid and 21 ml of water was cooled to -10° and 1.56 g (22.7 5 mmol) of sodium nitrate was added. After stirring at -5° for ten minutes, 8.1 ml (78 mmol) of cold 50% hypophosphorous acid was added and stirring was continued for another 10 minutes at -5°. A solution of 2.5 g (8.4 mmol) of 2-guanidino-4-(2—amino— 4— 10 imidazoyl) thiazole dihydrochloride in 100 ml of water was added dropwise over 0.5 hoar. The reaction was stirred at 50° for 2 hours, then at room temperature for 16 hours. The reaction mixture was diluted with 500 ml of water, made basic with solid sodium carbonate 15 and extracted three times with 150 ml portions of ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulfate, filtered, and evaporated leaving a solid. This solid was taken up into boiling methanol, decolorized with charcoal, and concentrated to a small 20 volume. The resulting solid was collected and dried, thereby affording 90 mg (5%) of 2-guanidino—4—(4— imidazoyl)thiazole^identical to the material of Example 31 by thin layer chromatography and high resolution mass spectrometry. 25 Example 33
3-Bromo-4-metho xy-3-buten-2-one 5.0 g (30 mmol) of 3-bromo-4-hydroxy—3-buten-2-one was dissolved in a solution of 100 ml tetrahydrofuran and 10 ml water. To the solution was added 8.7 ml 30 (90 mmol) of dimethylsulfate and 8.3 g (100 mmol) of sodium bicarbonate. The slurry was stirred at 25° for 7 5 minutes and the* solvent was removed in vacuo. The resultant oil and solid were stirred overnight in a
mixture of 20 ml die thy lether and 150 ml 0.1N sodium bicarbonate solution. The aqueous layer was separated and extracted with 2 x 50 ml ether and the combined ether extracts were washed with saturated sodium 5 chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuo to a yellow oil which soon solidified to afford 3.21 g (59%) of 3-bromo-4-methoxy-3-buten-2-one, mp 53-6°. nmr (DMSO-d-)
1 • 6
( S )•■ 8.22 (S, 1H); 4.03 (s, 3H); 2.37 (s, 3H); 10 Calcd. for C5H7Br02: C, 33.55; H, 3.94; Br, 44.64;
found: C, 33.27; H, 3.85; Br, 43.46.
Example 3 4 1-( 2-mefchyl^-4-imidazolyl )ethanone 6.3 g (35 mmol) of 3-bromo-4-metho>y-3-buten-2-one, 15 16.7 g acetamidine hydrochloride (175 mmol) and 29.2 ml triethylamine (210 mmol) were combined in 300 ml tetrahydrofuran and heated at reflux for 6 hours. The solvent was removed iji vacuo to a crude orange solid. The crude solid was dissolved in 200 ml ethyl 20 acetate and concentrated to 25 ml by boiling off the solvent. Cooling in ice resulted in crystallization of a yellow solid. This was collected by filtration, washed first with ethyl acetate, then with ether and dried at 25° in vacuo to give 9.995 g (23%) of l-(2-methyl-4-25 imidazolyl)ethanone, mp 124-7°. nmr (DMSO-dg) (/ ): 4.61 (s, 1H); 1.41 (s, 3H); 1.39 (s, 3H).
Example 35 1- ( 2-rr.ethy 1 - 4-imidazolyl)ethanone 5.75 g (46.3 mmol) of 1-( 2-methyl-l-irnidazolyl) -ethanone was dissolved in 600 ml tetrahydrofuran and 5 phqtolyzed in a quartz flask with a short wave u.v. light source (2537 nm) for 18 hours. The tetrahydrofuran solution was concentrated in vacuo to an oil and chromatographed on silica gel using 5% methanol in chloroform as eluent to give 2.6 g (45%) l-(2-methyl-4-10 inidazolyl)ethanone, mp 123-5°.
Example 3 6
1-(2-Methyl-4-imidazolyl)-2-bromoethanone hydrobromide
2.40 g (19.3 mmol) of 1-(2-methyl-4-imidazolyl) ethanone was dissolved in 30 ml of 48% hydrogen bromide. 15 To the stirred solution at 25° was added over a 5 minute period 3.36 g (21 mmol) of bromine dissolved in 5 ml 4 8% hydrogen bromide. The reaction was heated to 70° for 2.5 hours and then concentrated in vacuo to a dark oil. A mixture of isopropyl alcohol/ether was 20 added and trituration of the oil gave a solid. This .was collected by filtration and washed with ether to give 2.8 g (51%) of 1-(2-methy1-4-imidazolyl)—2-bromoethanone hydrobromide, mp 181°(dec.); nmr (DMSO-dg) (<f): 8.71 (s, 1H); 4.77 (s, 2H); 2.63 (s, 3H) .
07:
$ ^
Exampie 37
2-Guan id ino- 4 - ( 2-methyl-4--inidazo?.yI ) thiar.ol e 2.8 g (9.86 mmol) of 1-(2-methyl-4-imidazolyl)-2-bromo ethanone hydrobromide was dissolved in 10 ml 5 water. Saturated sodium bicarbonate solution was added to pH 10 and the resultant solid was collected by filtration and washed with 15 ml water. The dried free base was heated at reflux in 50 ml acetone. To the refluxing clear acetone solution was added 1.2 g 10 (5.86 mmol) of amidinothiourea. Solution occurred immediately and within a minute a solid began to form. After 1 hour reflux the slurry was cooled and the solid was collected by filtration and was washed with acetone followed by ether to give 2.37 g (79%) of 2-guanidino-15 4-(2-methyl-4-iinidazolyl)thiazole hydrobromide, mp
158° (dec.); nmr (DMSO-dg) {£ ): 7.71 (s shoulder on broad s, 1H); 7.56 (broad s, 4H); 4.32 (s, 1H); 2.51 (s, 3H); calcd. for CgH-^NgS.HBr: C, 31.69; E, 3.66; 27.72; found: C, 31.46; E, 4.30; N, 27.28.
Exampie 33 1-Acety1-4-methylimidazole A mixture of 50 g ( 609 mmol) of 4-rnethylimidazole in 2 50 ml of toluene was stirred at room temperature 5 under nitrogen and 239 g (304 mmol) of acetyl chloride was added. . The mixture was stirred at room temperature for 5 hours, filtered to remove insolubles and the filtrate concentrated giving 19 g (50%) of l-acetyl-4— methyl-imidazole as a yellow oil which crystallizes 10 on standing. nmr (CDC13) (/ ) : 8.06 (s, 1H); 7.17 (s,lH); 2.57 (s, 3H); 2.23 (s, 3H).
Example 39 5-Acety1-4-methylimidazole A solution of 5.0 g (40.3 mmol) of l-acetyl-4— 15 methylimidazole in 70 0 ml of dry tetrahydrofuran was ■ photolyzed in a quartz flask with a short wave ultraviolet light source (254 nm) for 24 hours. The tetrahydrofuran solution was concentrated in vacuo to give an oil which was chromatographed on silica gel using 20 5% methanol in chloroform as eluent to give 1.91 g
(38%) of 5-acetyl-4-methylimidazole as a white solid, rap 140-142°. nmr (CDCl^/DgDMSO) (/): 7.45 (s, 1H) ; 2.52 (s, 3H); 2.4 8 (s, 3H).
Example 4 0
1-(4-Methyl-5-imidazolyl)-2-bromoethanone
A solution of 1.57 g (12.6 mmol) of 5-acetyl-4-methylimidazole in 15 ml of concentrated hydrobrornic acid was warmed to 50° and a solution of 2.01 g (12.6 mmol) of bromine in 15 ml of concentrated hydrobrornic acid 30 was added over 0.75 hour. The mixture was stirred at 5 0° for 1.2 5 hour, then concentrated. The residue was triturated with isopropyl alcohol and the white solid was collected by filtration. This amounted to 2.78 g (78%) of 1-(4-methyl-5-imidazolyl)-2-bromoethanone 35 hydrobromide: nmr (DgDMSO) (/): 9.40 (s, 1H); 4.87
(s, 2H); 2.65 (s, 3H). This material was converted to
its free base by stirring for 15 minutes in 50 ml of . saturated sodium bicarbonate solution to give, after collection by filtration and drying, 1-(4-raethyl-5-imidazolyl)-2-bromoethanone as a white powder.
Example 41
2-Guanidino-4-(4-methy1-5-imidazolyl)thiazole hydrobromide
A mixture of 1.65 g (8.13 mmol) of l-(4-methyl-5-imidazolyl)-2-bromoethanone in 165 ml of acetone was heated until homogeneous. 0.96 g (8.13 mmol) of 10 anidinothiourea was added and the mixture was heated at reflux for 1 hour. The mixture was allowed to cool to room temperature and the resulting precipitate was collected by filtration. This solid amounted to 0.98 g (40%) of 2-guanidino-4-(4-methyl-5-imidazolyl)thiazole 15 hydrobromide, mp 2 45° (dc); nmr (D^DMSO) (<f ): 8.52 ' (s, 1H); 7.67 (b, 4H); 7.20 (s, 1H); 2.49 (s, 3H) .
Anal Calcd. for C^H^ qN^S.HBr: C, 31.69, H, 3.66; N, 27.72; Found: C, 31.80; H, 3.90; N, 26.90.
Example 4 2
2 0 l-Acetyl-2,4-dimethylimidazole
A solution of 9.6 g (0.10 M) of 2,4-dimethylimidazole in 50 ml of chloroform and 50 ml of toluene was stirred at room temperature and 3.6 ml (0.05M) of acetyl chloride was added via syringe over 1 minute. •25 The mixture was stirred at room temperature for 2 hours, then the mixture was filtered to remove insoluble solids, and the filtrate concentrated leaving 6.9 g (100%) of l-acetyl-2,4-dimethylimidazole as a white crystalline solid: nmr (CDC13) (</ ): 7.00 (s, 1H); 2.68 (s, 3H); 30 2.57 (s, 3H); 2.21 (s, 3H).
Example 43 5-Acetyl-2,4-dinethy.1 imidazole A solution of 6.9 g (0.05 M) of l-acetyl-2,4-dimethylimidazole in 700 ml of dry tetrahydrofuran was 5 photolyzed in a quartz flask with a short wave ultraviolet light source (254 nn) for 40 hours. The tetrahydrofuran' solution was concentrated in vacuo to give an oil which was chromatographed on silica gel using 5% methanol in chloroform as eluent to give 2.8 g 10 (41%) of 5-acetyl-2,4-dimethylimidazole as a white solid, mp 83-87°. Recrystallization from isopropyl ether gave analytically pure material, mp 87-SS°. n-T.r (CDC13) (£ ) : 2.53 (s, 6H); 2.40 (s, 3H).
Anal. Calcd. for C7H1QN20: C, 60.85; H, 7.30; N, 20.27; 15 found: C, 6 0.66; H, 7.26; N, 2 0.09.
Example 4 4
1- ( 2,4-Dimethyl-5-imidazolyl)-2-bromoethanone
A solution of 1.0 g (7.24 mmol) of 5-acety1-2,4-dimethy1imidazole in 15 ml of concentrated hydrobrornic . 20 acid was warmed to . 50° and 1.16 g {1-25 mmol) of bromine was added dropwise over 1 minute. The mixture was then heated at 50-60° for 1 hour. The mixture was concentraed and the solid residue was triturated with 30 ml of saturated sodium bicarbonate solution. The insoluble 25 material was collected by filtration, washed with water, and cried ijn vacuo to give 1.12 g (71%) of l-(2,4-dimethyl-5-imidazolyl)-2-bromoethanone as a white solid, . mp 128-132°. nmr (DgDMSO) (/ ): 4.40 (s, 2H); 2.27 (s, 3H); 2.13 (s, 3H).
. -41-Exomple 4 5
2—Guanidino-4-(2, 4-dimethy1-4-imidazoIvl)thiazole hydrobromide hamihydrate A solution of 1.0 g (4.6 mmol) of 1—(2,4-5 dinethy1-5-imidazolyl)-2-bromcathanone in 50 ml of acetone was warmed and 0.55 g (4.6 mmol) of amidino-thiourea was added. The mixture was heated at reflux for 1 hour, during which time a white solid precipitated. The precipate was collected, washed with acetone, and 10 cried tc give 1.12 a (77%) of 2-guanidino—4—{2f4—dimethyl 5-imidazolyl) thiazole hydrobromide hemihydrate as a white solid, mp 2 73° (dc). nmr (DgDMSO) (J* ): 8.4—7.2 (b, 7H}; 7.00 (s, 1H); 2.50 (s, 3H); 2.38 (s, 3H).
Anal. Calcd. for C7H12NfiS,aEr.l/2H,Or C, 33.14; 15 2, 4.33; N, 2 5.76; S. 9.33. Found: C, 33.47; H, 4.19; N. 25.93; S. 9.91.
E xamp 1 e 4 6 2-Guanidino-4- (2-N-phenyj.ar,uno-4-imidazolyl)thiazole 20. A mixture of 2.3 g (8.5 mmol) of 2-ainino— 1—
(2-guanidino-4-thiazolyl)ethanone dihydrochloride, 2.0 g (17 mmol) of M-phenylcyanamide and 40 ral of warer was heated at 50° for 19 hours. The dark solution was filtered to remove insolubles, and the 25 filtrate was washed with chloroform. The aqueous filtrate was made basic with saturated sodium bicarbonate solution and the resulting precipiate was collected by filtration, washed with water, ether,
then acetonitrile to give a brown solid. This was
I
disso.lved in ethanolic hydrogen chloride and ether was added resulting in the precipitation of a solid. Recrystallization from n-propanol/acetonitrile gave
4 79 mg of 2-guanidino-4-(2-N-pnenylamino-4-imidazolyl) 5 thiazole dihydrochloride, mp 245-247° (dc). nmr
(DgDMSO) (/ ): 8.2-8.0 (b, 4H); 7.76 (s, IK); 7.4-7.0 (s + b, 5H) . High resolution mass spectrum, calcd. for c13h13N7S: 299.0953; found: 299.0964.
Example 4 7
3-Bromo-4-ethoxy-3-buten-2-one
A mixture of 400 ml absolute ethanol and 60 ml toluene was heated to reflux and 20 ml of azeotrope was removed via a Dean Stark trap. To the ethanol-toluene solution was added 33.0 g (0.2 mol) of 3-bromo-4-hydroxy-15 3-buten-2-one and reflux was continued for 2 hours during which period three aliquots of 20 ml of ethanol-toluene were removed via the trap. The solution was concentrated in vacuo to give 38.6 g (100%) of 3-bromo-4-ethoxy-3-buten-2-one as a mobile oil. 20 nmr (DMSOd-6) </ ): 8.21 (s, IK); 4.23 (q, 2H) ; 2.33 (s, 3H); 1.31 (s, 3H).
Example 4 8 2-Hydroxymethy 1-4 -acetyl imidazole 9.7 g (0.05 mol) of 3-bromo-4-ethoxy—3-buten 25 -2-one was combined with 5.53 (0.05 mol) of hydroxy-acetamidine hydrochloride in 100 ml acetone to form a slurry. To the slurry at 25° was added 11.5 g (0.1 nol) of 1,1,3,3-tetramethylguanidine over a period of
minutes. After stirring for 4 8 hours the slurry
was filtered and the mother liquors were concentrated _in
A 0 /
i ^
-an T*j
vacuo to an oil which was chromatographed on silica gel 60 (E. Merck) using chloroform as eluent to give , 1.48 g (21%) of 2-hydroxymethyl-4-acetylimidazole, rnp 147-148°. nmr (DMSO-dg) (/): 7.73 (s, 1H); 5.46 5 (very broad s, 1H); 4.5 (broad s, 2H); 2.4 (s, 3H).
Example 49
2-Hydroxymethy 1-4-br omo acetyl imidazole hydrobroniide
1.826 g (0.013 mol) of 2-hydroxymethyl—4—
acetylimidazole was dissolved in 40 ml of 48% hydro-
bromic acid and 2.1 g (0.013 mol) of bromine was added. The reaction was warmed at 80° for 2 hours and then concentrated _in vacuo to a solid. This material was triturated with isopropylether and the resultant solid was collected by filtration and was
washed with ether and dried to give 2.2 g (56%) of 2-
hydro xvrnethy 1-4 -bromoac ety 1 imidazo 1 e hydrobromide,
mp 183° with decomposition. nmr (DKSO-d^) (/ ):
b
8.a (s, 1H); 4.8 (s, 2 x 2H) .
Example 50 2-Guanidino-4-(2-hydroxymethyl-4-imidazoly1)thiazole hydrobromide 1.78 g (0.0059 mol) of 2-hydroxymethyl-4-bromoacetylimidazole hydrobromide was dissolved in water and saturated sodium bicarbonate solution was 25 added to precipitate the free base. This material was collected by filtration and dried and combined with 55 6 mg (0.0081 mol) of amidinothiourea in 60 ml acetone and heated to 70°. After 15 minutes heating a solid formed. The reaction mixture was cooled and the 30 resultant solid was collected by filtration to give 1.65 g (87%) 2-guanidino-4-(2-hydroxymethyl-4— imidazolyl)thiazole hydrobromide, mp>310°. A sample
/
vvas converted to the free base by dissolving in hot water and adding sodium bicarbonate solid to pH 10
to precipitate 2-guanidino-4-{2-hydroxymethy1-4-
imidazolyl)thiazole free base. This material was
dried over toluene at high vacuum to give a light tan solid, mp 208-209° with decomposition. nmr (DMSO-d,.)
o
(/ ): 7.16 (s, 1H); 6.83 (broad s, 4H) 6.68 {s, 1H); 4.4 5 (s, 2H); 3.46 (very broad s, 1H). High resolution mass spectrum, calcd for CgH^gNgOS: 238.0638; found: 10 238.0654.
£ xamp1e 51
The gastric acid antisecretory activity of compounds of the present invention was determined in overnight fasted, conscious Heidenhain pouch dogs. 15 Pentagastrin (Pentavlon-Ayerst was used to stimulate acid output by continuous infusion into a superficial leg vein at doses earlier determined to stimulate near maximal acid output from the gastric pouch. Gastric juice was collected at 30 minute intervals following the 20 start of a pentagastrin infusion and measured to the nearest 0.1 ml. Ten collections were taken for each dog during an experiment. Acid concentration was determined by titrating 1.0 ml of gastric juice to pH 7.4 with 0.1N sodium hydroxide using an Autoburette and a glass 25 electrode pH meter (Radiometer).
Drug or vehicle was given intraveneously 90 minutes following the start of the pentagastrin infusion, at a dose of 1 mg/kg. Gastric acid antisecretory effects were calculated by comparing the lowest acid output 30 after drug administration with the mean acid output immediately before drug.
-4 5-
The results obtained showed that the compounds of Examples 4, 5,' 6, 7, 11, 13, 13, 17, 20, 21, 22, 23, 24, 25, 26, 27, 28, 31, 37, 41, 45 and 50, all inhibited gastric acid secretion at least 15% at a dose of 1 mg/kg.
E xamp1e 5 2
The histamine-^ antagonist activity of compounds of the present invention was determined by the following procedure:
Guinea pigs are killed rapidly with a blow to the 10 head, the heart removed and the right atria dissected free. Atria are suspended, isometrically, in a temperature-controlled (32°+2°) tissue bath (10 ml containing oxygenated (95% 02; 5% C02) Krebs-Henseleit buffer (pH 7.4) and are allowed to stabilize approximately 15 one hour during which time the tissue bath is flushed several times. Individual atrial contractions are followed with a force-displacement transducer connected to a cardiotachometer and Grass polygraph recorder.
After obtaining a dose-response curve to histamine, the 2 0 bath containing each atrium is flushed several times with fresh buffer and the atria re-equilibrated to basal rates. Following the return to basal rate, test compounds axe added at selected final concentrations and the histamine dose-response curve is again determined 25 in the presence of antagonist. Results are expressed as dose-ratios, the ratio of histamine concentrations required to produce one-half of maximal stimulation in the presence and absence of antagonist, and the apparent dissociation constant of the H2~receptor antagonist pA2, 30 is determined. The results obtained showed that the compounds of Examples 4, 5, 6, 7, 11, 13, 15, 17, 20, 21, 22, 23, 24, 25, 26, 27, 28, 31, 37, 41, 45, 46 and 50 have pA2 values of greater than 5.7.
A
Claims (1)
- WHAT WE CLAIM IS: 207258 A compound of the formula H and the acid addition salts thereof, wherein R* is hydrogen, hydroxymethyl, alkyl of 1 to 6 carbon atoms or -(CH2)nAr, wherein n is an integer from 2 to 4; R" is hydrogen or methyl; Ar is phenyl or phenyl monosubstituted with chloro, bromo, fluoro, alkyl' of 1 to 3 atoms or alkoxy of 1 to 3 carbon atoms;;and Rg is halo.;2. A compound as claimed in claim 1 substantially as hereinbefore described with reference to' any example thereof.;pa-ZQg-;By>ff*/Tb®lr authorised Agmte, A. Per
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19623180A | 1980-10-14 | 1980-10-14 | |
| US06/293,574 US4374843A (en) | 1980-10-14 | 1981-08-20 | 2-Guanidino-4-heteroarylthiazoles |
| NZ198629A NZ198629A (en) | 1980-10-14 | 1981-10-13 | 2-guanidino-4-heteroaryl thiazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ207258A true NZ207258A (en) | 1985-02-28 |
Family
ID=27353483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ20725881A NZ207258A (en) | 1980-10-14 | 1981-10-13 | Substituted imidazoles |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ207258A (en) |
-
1981
- 1981-10-13 NZ NZ20725881A patent/NZ207258A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4374843A (en) | 2-Guanidino-4-heteroarylthiazoles | |
| US5880135A (en) | Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them | |
| EP0003640B1 (en) | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | |
| EP0506194B1 (en) | 4-aryl-thiazole or imidazole derivatives | |
| EP0161841B1 (en) | 2-(n-substituteguanidino)-4-hetero-arylthiazole antiulcer agents | |
| CA2011222A1 (en) | Benzimidazole and azabenzimi-dazole derivatives, their methods of preparation, synthesis intermediates and pharmaceutical compositions in which they are present and which are useful especially for the treatment of cardiovascular diseases and duodenal ulcers | |
| US6344470B1 (en) | Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same | |
| CA1138451A (en) | 2-imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same | |
| US4602093A (en) | Novel substituted imidazoles, their preparation and use | |
| US4490527A (en) | Benzo-fused heterocyclic anti-ulcer agents | |
| US4435396A (en) | Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor | |
| JPS6157307B2 (en) | ||
| US4590299A (en) | 2-guanidino-4-heteroarylthiazoles | |
| US3530140A (en) | Certain pyridyl-hydrazino-2-yl-imidazolines | |
| US4452987A (en) | Haloacetyl imidazoles | |
| NZ207258A (en) | Substituted imidazoles | |
| EP0134096B1 (en) | Aminopyrimidinone derivatives as histamine h2-antagonists | |
| KR20010031297A (en) | 2-Substituted 1,2-Benzisothiazole Derivatives and Their Use as Serotonin Antagonists (5-HT1A, 5-HT1B and 5-HT1D) | |
| EP0074229B1 (en) | Triazole gastric anti-secretory agents | |
| US4510313A (en) | 2-Guanidino-4-heteroarylthiazoles | |
| US4808727A (en) | Imidazolium hydrogen carbonates | |
| US4711889A (en) | Schistosomicidal acridanone hydrazones | |
| NZ207257A (en) | 2-guanidino-thiazoles | |
| EP0081955B1 (en) | Benzo-fused heterocyclic compounds | |
| NZ206317A (en) | Acridanone derivatives and pharmaceutical compositions |